A 28-year-old male with schizophrenia has agreed to start paliperidone palmitate (Invega Sustenna) long-acting injectable after multiple relapses from oral medication nonadherence. The PMHNP explains the initiation protocol. Which of the following correctly describes the loading dose strategy for paliperidone palmitate and why it is necessary?